bioRxivPharmacology & ToxicologyPreprint
Fragment Covalent Bond Formation at SOS1 Tyr-884 Inhibits KRAS Nucleotide Exchange
Khuchtumur Bum-ErdeneiD, Giovanni Gonzalez-Gutierrez, Mona K GhozayeliD, Samy MerouehiD
Abstract
The activation of the KRAS oncogene from its inactive GDP-bound state to its active GTP-bound state is mediated by Son of Sevenless (SOS) exchange factors. Small-molecule inhibition of SOS1 has been achieved, with three compounds currently in clinical trials. These compounds bind to SOS1 and disrupt a crucial interaction between SOS1 Tyr-884 and KRAS Arg-73. Here, we screen libraries of aryl sulfonyl fluorides to explore covalent bond formation at Tyr-884 as a strategy for covalent inhibition of SOS1-KRAS binding. Initially, ten fragments were tested and several inhibited KRAS nucleotide exchange by SOS1. X-ray crystal structures revealed that one reaction site for the fragments was Tyr-884, but mass spectrometry and nucleotide exchange assays with wild-type and mutant SOS1 indicated additional reaction sites. To identify candidates specific to Tyr-884, we conducted a larger screen and identified fragment 11 (SOF-599). The fragment formed an adduct predominantly at Tyr-884 and inhibited KRAS nucleotide exchange by SOS1 in a time- and concentration-dependent manner. Fragment 11 (SOF-599) exhibited a half-maximal inactivation concentration (KI) of 12 micromolar and a reaction half-life of 6 h. These findings establish 11 (SOF-599) as a promising starting point for the development of covalent SOS1 inhibitors as an alternative strategy to existing non-covalent antagonists.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Atomic-scale mechanisms of GDP extraction by SOS1 in KRAS-G12 and KRAS-D12 oncogenes
Zheyao Hu, Jordi Martı́·Computers in Biology and MedicinePeer-reviewed·Dec 28, 2024
- Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
L. Goebel, T. Kirschner, … D. Rauh·bioRxiv·Jul 25, 2022
- Kinetic and Redox Characterization of KRAS G12C Inhibition
M. V. Huynh, D. Parsonage, … S. L. Campbell·bioRxiv·Apr 3, 2022
- Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector binding
M. J. McCarthy, C. V. Pagba, … A. A. Gorfe·bioRxiv·Oct 11, 2018
- KRAS G12D can be targeted by potent salt-bridge forming inhibitors
- Strain-release alkylation of Asp12 enables mutant selective GTP-state targeting of K-Ras(G12D)